Navigation Links
New drug shows promise against multiple sclerosis
Date:11/1/2011

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men.

The study, carried out by researchers at the University of California, San Francisco (UCSF) Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British medical journal Lancet.

The study involved patients with relapsing-remitting MS, a form of the disease marked by the accumulation of lesions in the brain and spinal cord and periodic "attacks" of neurological impairment.

The 220 patients were randomly enrolled into four groups two that received injections of the monoclonal antibody Ocrelizumab at two different doses, one that received the standard multiple sclerosis drug interferon-beta, and one "control" group that was given a placebo.

The doctors gauged the effectiveness of each treatment by performing monthly magnetic resonance imaging (MRI) brain scans of the patients and counting the number of visible marks that indicate inflamed lesions, a hallmark of the disease. They also compared the severity and frequency of neurological "attacks" that cause loss of vision, incoordination, weakness and numbness, among other symptoms.

The results of this trial showed that patients who received the drug generally fared well and showed fewer signs of the disease than patients who receive a placebo or the standard Interferon treatment. Overall, the trial found that Ocrelizumab led to a 89 percent reduction in the formation of brain lesions, and it also reduced the number of new multiple sclerosis attacks over 24 weeks. During this relatively short-term study, interferon performed no better than placebo on these outcomes.

"It really is
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Preterm birth rate shows three year improvement in most states
2. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
3. Novel approach to treat proliferative vitreoretinopathy shows promise
4. New therapy shows promise for treating cardiovascular disease
5. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
6. New oncolytic virus shows improved effectiveness in preclinical testing
7. Clinical trial shows first evidence that anal cancer is preventable
8. Through-the-nipple breast cancer therapy shows promise in early tests
9. Compound found in common wart treatment shows promise as leukemia therapy
10. Study shows why underrepresented men should be included in binge eating research
11. HIV Medication Patch Shows Promise in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an annual ... raising money for breast cancer research. Pelican Water is ... in the effort to find a cure. , ... having access to clean, healthy water. Research has shown ... forms of cancer. , The Problem of Chlorine ...
(Date:10/1/2014)... Washington, DC (PRWEB) October 01, 2014 ... of all retail generics increasing in price in the ... Information Services, Inc.’s (AIS) Drug Benefit News (DBN) interviewed ... this trend means for pharmacies and health plans. ... pace with rising generic acquisition costs, these cost increases ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3
... the U.S. and Canada have been selected to participate ... initiative in immunotherapy funded by the National Cancer Institute ... will establish a network of top academic immunologists to ... patients, own immune systems to fight their cancer. , ...
... , WEDNESDAY, April 6 (HealthDay News) -- Poor ... have the condition diagnosed, but this disparity has decreased in ... data on children in California and found that the average ... born in 1992 to 3.8 years for those born in ...
... the April 5 White House Press Briefing, President Barack Obama ... in Congress from both political parties in order to avoid ... he has matched the initial House of Representatives, proposal to ... only in areas of priority. He expressed that neither side ...
... neonatal horse can be a challenging patient. Its immune system is ... like most infants it wants to stay close to mom. ... Pamela Wilkins , a professor of equine internal medicine and ... a new paper on equine neonatal intensive care. The ...
... to find such high levels of PCBs, highly toxic compounds ... a region such as the western coast of Africa", Ailette ... (UPV/EHU-Spain) and co-author of a study published in the journal ... which some studies have shown to be carcinogenic compounds, were ...
... over, newts and salamanders. The mouse may join you as ... Researchers are reporting that a simple chemical cocktail can coax ... in the first stages of a regenerating limb. Their study, ... the biological raw material for a new limb, appears in ...
Cached Medicine News:Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 3Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 4Health News:Autism Diagnoses Still More Likely in Richer Neighborhoods 2Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2Health News:Treating newborn horses: A unique form of pediatrics 2Health News:Treating newborn horses: A unique form of pediatrics 3Health News:High levels of toxic compounds found on coasts of West Africa 2
(Date:9/30/2014)... Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... Hologic,s President and Chief Executive Officer, will preside over ... 1, the first day of Breast Cancer Awareness Month. ... campaign focused on the important benefits of Hologic,s 3D ... FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... 13 Dynatronics Corporation (Nasdaq: DYNT ) today announced ... , Net income for the fiscal first quarter was $68,625 ... ($.01 per share) for the comparable prior year period. Sales ... $7,996,149 for the first quarter of the prior fiscal year. ...
... Eli Lilly and Company (NYSE: LLY ) announced ... science and technology, and president, Lilly Research Laboratories, will ... also announced that Jan M. Lundberg, Ph.D., executive vice ... to become his successor. Paul is committed to working ...
Cached Medicine Technology:Dynatronics Announces Positive Financial Results for Quarter 2Dynatronics Announces Positive Financial Results for Quarter 3Dynatronics Announces Positive Financial Results for Quarter 4Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 2Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 3
... AFP IRMA,is an immunoradiometric assay ... (AFP) in serum. It is,intended ... in either of,two contexts:, (a) ... the,management of patients with,nonseminomatous testicular ...
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
The MOSAIC PET scanner is designed to meet the exacting requirements of animal research imaging. Supported by proven Philips technology, MOSAIC provides a leading edge PET solution for reliable in-vi...
... EEG recording is assured even in the ... has high performance, high sensitivity amplifiers, high ... filter, shielded electrodes and a high performance ... is a complete and ready to ...
Medicine Products: